QUEBEC CITY, Feb. 28, 2017 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has received final approval for the
listing of the Corporation's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX").
The Common Shares will commence trading on the TSX effective as of the open of the market on March 1, 2017. Upon
listing on the TSX, the Common Shares will continue to trade under the symbol "OPS". In conjunction with listing on the TSX,
the Common Shares will be voluntarily delisted from the TSX Venture Exchange prior to the commencement of trading
on March 1, 2017.
"This is a significant achievement for Opsens," said Louis Laflamme, President and Chief
Executive Officer of Opsens. "The TSX is Canada's most significant stock exchange and this move
will provide us with greater visibility in the marketplace and access to a broader and more diverse range of international and
institutional investors. This move will also help Opsens develop a stronger profile in the investment community, as our
penetration grows, on a global scale, in the field of interventional cardiology," Mr. Laflamme added.
Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a nitinol-based, fiber optic guidewire. The
OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is
immune to undesired effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR
measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that
provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources,
the FFR market represented more than US$300 million in sales in 2014 and is expected to reach
US$1 billion in the medium-term.
About Opsens Inc. ( www.opsens.com
or www.opsensmedical.com
)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also
involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for
critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
To view this news release in HTML formatting, please use the following URL:
http://www.newswire.ca/en/releases/archive/February2017/28/c3795.html